Industry
Biotechnology
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Loading...
Open
10.32
Mkt cap
259M
Volume
538K
High
10.47
P/E Ratio
-38.54
52-wk high
11.11
Low
8.43
Div yield
N/A
52-wk low
3.03
Portfolio Pulse from
November 13, 2024 | 1:15 am
Portfolio Pulse from
November 12, 2024 | 9:15 pm
Portfolio Pulse from
November 06, 2024 | 9:45 pm
Portfolio Pulse from Benzinga Insights
October 28, 2024 | 5:01 pm
Portfolio Pulse from Benzinga Newsdesk
October 28, 2024 | 2:38 pm
Portfolio Pulse from Benzinga Newsdesk
October 04, 2024 | 1:48 pm
Portfolio Pulse from Avi Kapoor
October 04, 2024 | 12:50 pm
Portfolio Pulse from Benzinga Newsdesk
October 04, 2024 | 10:28 am
Portfolio Pulse from Benzinga Newsdesk
October 03, 2024 | 6:55 pm
Portfolio Pulse from Benzinga Newsdesk
October 03, 2024 | 10:35 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.